Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

The economic impact of neuropsychiatric symptoms in Alzheimer's disease: can drugs ease the burden?

Murman DL, Colenda CC.

Pharmacoeconomics. 2005;23(3):227-42. Review.

PMID:
15836005
2.

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A.

Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160. Review.

3.

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.

Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C.

Health Technol Assess. 2005 Apr;9(15):1-157, iii-iv. Review.

4.
5.

Assessing health economic outcome in Alzheimer's disease clinical trials.

Jonsson L.

J Nutr Health Aging. 2007 Jul-Aug;11(4):353-5. Review.

PMID:
17653498
6.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
7.

Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease.

Jönsson L.

Pharmacoeconomics. 2003;21(14):1025-37. Review.

PMID:
13129415
9.

Economics of dementia and pharmacoeconomics of dementia therapy.

Fillit H, Hill J.

Am J Geriatr Pharmacother. 2005 Mar;3(1):39-49. Review.

PMID:
16089246
10.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

11.

The needs of the caregiver in the long-term treatment of Alzheimer disease.

Bullock R.

Alzheimer Dis Assoc Disord. 2004 Apr-Jun;18 Suppl 1:S17-23. Review.

PMID:
15249844
12.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

13.
14.

Practical treatment strategies for patients with Alzheimer's disease.

Christensen DD, Lin P.

J Fam Pract. 2007 Dec;56(12 Suppl New):S17-23. Review.

PMID:
18664338
15.

The use of cognitive enhancers in behavioral disturbances of Alzheimer's disease.

Miller LJ.

Consult Pharm. 2007 Sep;22(9):754-62. Review.

PMID:
18198970
16.

[Therapy of Alzheimer disease].

Kovács T.

Neuropsychopharmacol Hung. 2009 Mar;11(1):27-33. Review. Hungarian.

18.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

19.

Behavioral effects of current Alzheimer's disease treatments: a descriptive review.

Cummings JL, Mackell J, Kaufer D.

Alzheimers Dement. 2008 Jan;4(1):49-60. doi: 10.1016/j.jalz.2007.10.011. Review.

PMID:
18631950
20.

Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales.

Tariot PN, Loy R, Ryan JM, Porsteinsson A, Ismail S.

Adv Drug Deliv Rev. 2002 Dec 7;54(12):1567-77. Review.

PMID:
12453674
Items per page

Supplemental Content

Support Center